» Articles » PMID: 38731276

Diagnosis of Canine Tumours and the Value of Combined Detection of VEGF, P53, SF and NLRP3 for the Early Diagnosis of Canine Mammary Carcinoma

Overview
Journal Animals (Basel)
Date 2024 May 11
PMID 38731276
Authors
Affiliations
Soon will be listed here.
Abstract

The average life of a dog is generally maintained at ten to fifteen years, and tumours are the predominant reason that leads to the death of dogs, especially canine mammary carcinoma. Therefore, early diagnosis of tumours is very important. In this study, tumor size, morphology, and texture could be seen through general clinical examination, tumor metastasis could be seen through imaging examination, inflammatory reactions could be seen through hematological examination, and abnormal cell morphology could be seen through cytological and histopathological examination. In the 269 malignant cases and 179 benign cases, we randomly selected 30 cases each, and an additional 30 healthy dogs were selected for the experiment (healthy dogs: dogs in good physical condition without any tumor or other diseases). We used RT-qPCR and ELISA to determine the relative expression of vascular endothelial growth factor (VEGF), tumor protein P53 (P53), serum ferritin (SF), and NOD-like receptor protein 3 (NLRP3) in 30 healthy dogs, 30 dogs with benign mammary tumours, and 30 dogs with malignant mammary tumours. In the results, the same expression trend was obtained both in serum and tissues, and the expression of the four markers was the highest in malignant mammary tumours, with highly significant differences compared with the benign and healthy/paracancerous groups. By plotting the ROC curves, it was found that the results of combined tests were better than a single test and the combination of the four markers was the best for the early diagnosis. In conclusion, this can assist the clinical early diagnosis to a certain extent, and also provides some references and assistance for the development of tumor detection kits in clinical practice.

References
1.
Sleeckx N, Van Brantegem L, Van den Eynden G, Fransen E, Casteleyn C, Van Cruchten S . Angiogenesis in canine mammary tumours: a morphometric and prognostic study. J Comp Pathol. 2013; 150(2-3):175-83. DOI: 10.1016/j.jcpa.2013.09.005. View

2.
Haga S, Nakayama M, Tatsumi K, Maeda M, Imai S, Umesako S . Overexpression of the p53 gene product in canine mammary tumors. Oncol Rep. 2001; 8(6):1215-9. DOI: 10.3892/or.8.6.1215. View

3.
Illei P, Shyu S . Fine needle aspiration of thymic epithelial neoplasms and non-neoplastic lesions. Semin Diagn Pathol. 2020; 37(4):166-173. DOI: 10.1053/j.semdp.2020.04.006. View

4.
Bronhara Pimentel P, Giuliano A, Beczkowski P, Horta R . Molecular Profile of Canine Hemangiosarcoma and Potential Novel Therapeutic Targets. Vet Sci. 2023; 10(6). PMC: 10302982. DOI: 10.3390/vetsci10060387. View

5.
Yang N, Zheng H, Yu C, Ye Y, Du C, Xie G . Research progress of good markers for canine mammary carcinoma. Mol Biol Rep. 2023; 50(12):10617-10625. DOI: 10.1007/s11033-023-08863-x. View